GET DAILY SIGNALSRegeneron (REGN) Surges +13% After Strong Q3 — Can It Reach $1,050?
Key Takeaways
- The central target examined here is $1,050, representing roughly 13% upside from the recent close near $928.
- This figure is not an analyst consensus. It reflects the top of the current Street range, anchored by JPMorgan's post-earnings objective of $1,050 and a cluster of other high targets between roughly $1,000 and $1,030.
- The post-earnings surge pushed REGN above the ~$869 consensus average target, so the remaining upside debate centers on the highest individual analyst objectives.
- Across roughly 28 analysts, current targets span from about $730 to $1,050, a wide range that signals genuine disagreement on how much pipeline execution is already priced in.
- The strongest supports are a blowout quarter — record Dupixent sales, accelerating Eylea HD growth, and strong Libtayo momentum — plus a $16.2 billion cash balance.
- The biggest risks are an overbought technical posture, a valuation now above the consensus fair value, and reliance on pipeline catalysts to justify further upside.
- For more detail, explore Regeneron's Major News, Today's Price Move, Forecast, and Earnings pages.
Analyst Price Targets and Consensus View
The $1,050 objective is best understood as a fallback benchmark rather than a consensus figure. According to data compiled from S&P Global, roughly 28 analysts rate the stock a "Buy" on average, with a mean 12-month target near $869 — a level now about 6% below the current share price. Because the post-earnings rally carried REGN above that average, the average analyst price target no longer offers a meaningful upside reference. The genuine upside question therefore shifts to the highest, most recently updated targets.
Following the third-quarter beat, JPMorgan raised its target to $1,050 from $950, Raymond James to $1,020 from $911, and Piper Sandler to $1,000 from $865. Guggenheim had already moved to $1,030, with TD Cowen at $980 and UBS — which upgraded the stock to Buy in October — at $978. On the more cautious side, Citi (Neutral) sits at $825, Baird (Neutral) at $875, and RBC (Sector Perform) at $810. That dispersion, from the mid-$700s to above $1,000, shows how differently analysts weigh the durability of Dupixent and the promise of Regeneron's pipeline. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
With shares near $928, reaching $1,050 would require a gain of about 13%, a substantial but not extreme move for a large-cap biopharma name. Third-quarter results provided the fundamental spark: revenue of $5.12 billion rose 36% year over year, while adjusted EPS climbed roughly 70% to $20.07, both well ahead of consensus. Dupixent, developed with partner Sanofi, posted record global sales near $6.5 billion, and high-dose Eylea HD grew U.S. revenue 62% to about $699 million.
Notably, however, combined U.S. Eylea sales were still down about 1%, underscoring that the franchise has not fully returned to growth. Some of the quarter's strength also reflected favorable gross-to-net pricing adjustments that may not repeat each period. The path to $1,050 likely requires continued Dupixent momentum, sustained Eylea HD conversion, and incremental pipeline or business-development catalysts.
What Could Support a Move Toward the Target
Several verified factors could underpin further gains. Dupixent's prescription momentum suggests durable underlying demand across its expanding indication set. Eylea HD's rapid conversion demonstrates Regeneron's ability to defend a key franchise against competition. A cash position of $16.2 billion, aggressive share repurchases, and strong free cash flow give management substantial strategic flexibility, including for business development. Analysts at Raymond James specifically argued the time has come for Regeneron to deploy that war chest more aggressively, and they flagged near-term catalysts such as CIDEB MASH data, a potential cemdisiran launch, and an Eylea HD prefilled syringe approval.
What Could Prevent the Target From Being Reached
The principal obstacle is valuation. After a one-day jump of 13%, REGN trades above the consensus target and roughly 20 times trailing earnings, and the market's fair-value estimates now sit modestly below the share price. Technical conditions are also stretched, with the relative strength index (RSI) in the late 70s — a level often associated with overbought conditions and short-term pullbacks. Leerink Partners and RBC each maintained neutral stances even while acknowledging the quarter's strength, arguing that further upside depends on pipeline success rather than the current commercial franchises. One-time pricing benefits and continued Eylea franchise pressure are additional risks.
Technical Levels and Market Structure
REGN broke decisively above its prior September high near $859 to print a new 52-week high of roughly $935. That breakout area now forms a potential support zone on any pullback, while the 52-week low near $591 highlights how far the stock has traveled. The $1,000 level represents the next psychological round number on the way toward $1,050, with the mid-$850s as a first area of interest for buyers on weakness.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms differ. The most important items to watch include upcoming earnings and guidance, revisions to Dupixent and Eylea estimates, clinical readouts across immunology, oncology and metabolic disease, regulatory decisions, and any shift in how analysts interpret the gross-to-net pricing dynamics that boosted the latest quarter.
Monitoring with AI Daily Buy/Sell Signals
In my research process, I often rely on Tickeron's AI Daily Buy/Sell Signals to get a systematic view of names like this. The tool applies artificial intelligence to scan thousands of stocks and ETFs, delivering Buy, Sell, or Hold signals based on market conditions and technical patterns. It helps me spot shifts more efficiently and serves as a useful complement to the fundamental work on a name such as REGN.
Final Assessment
Reaching $1,050 would require roughly a 13% advance from current levels — a realistic but far-from-guaranteed move that hinges less on Regeneron's core commercial franchises than on its pipeline and capital-deployment decisions. The bullish case rests on exceptional third-quarter execution, record Dupixent sales, and a fortress balance sheet. The bearish case points to a valuation that now exceeds the Street's average target, an overbought technical profile, and a wide analyst range that reflects real uncertainty about how much future growth is already reflected in the price. The $1,050 level is the top of the current analyst range rather than a consensus, and investors should treat it as a milestone to monitor rather than a foregone conclusion.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
REGN in upward trend: 10-day moving average broke above 50-day moving average on October 26, 2026
The 10-day moving average for REGN crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on REGN as a result. In 58 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 63%.
The Moving Average Convergence Divergence (MACD) for REGN just turned positive on October 14, 2026. Looking at past instances where REGN's MACD turned positive, the stock continued to rise in 32 of 50 cases over the following month. The odds of a continued upward trend are 64%.
REGN moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +14.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where REGN advanced for three days, in 202 of 314 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where REGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
REGN broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for REGN entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 5 (best 1 - 100 worst), indicating outstanding price growth. REGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 65 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.013) is normal, around the industry mean (3.162). P/E Ratio (22.161) is within average values for comparable stocks, (-1.064). Projected Growth (PEG Ratio) (1.238) is also within normal values, averaging (9.059). Dividend Yield (0.004) settles around the average of (131.622) among similar stocks. P/S Ratio (5.339) is also within normal values, averaging (439.647).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of medicines for the treatment of serious medical conditions
Industry Biotechnology
Advertisement